philochem
 
About-us technologies products Clinical-trials collaborations careers contact-us
 
 
News
 
Events
 
 

 

 

Events 2012

San Diego, USA, December 2nd-6th, 2012
Philogen's Scientific Director, Professor Dario Neri will deliver a Keynote presentation IBC's prestigious Antibody Therapeutics conference in San Diego, December 2nd-6th 2012. The title of the presentation is 'Delivering Immune Modulators to sub-endothelial extracellular matrix at sites of disease'.
 
Geneva, Switzerland, November 27th-28th, 2012
Philogen is pleased to announce that Professor Dario Neri and Dr Giulio Casi will present at the European Antibody Congress in Geneva, 27th-28th November 2012. The title of their talks are 'Armed antibodies: a critical comparison of different payloads' and 'Use of non-internalizing antibodies and of traceless linkers for ADC development' and the talks will highlight Philogen's recent clinical data and linkerless technology for the preparation of Antibody-Drug Conjugates.
 
Washington, USA, November 9th-14th, 2012
Philogen are pleased to announce that a poster entitled "A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX)" will be presented at the American College of Rheumatology (ACR)/ARHP Annual Meeting. This presentation will provide an update on the clinical results that have emerged since the presentation by Prof. Galeazzi, one of Philogen's clinical investigators, at EULAR earlier in the year.
 
Siena, Italy, June 19th, 2012
Philogen S.p.A is pleased to announce that positive data emerging from the Phase Ib Rheumatoid Arthritis clinical trial with DEKAVIL (F8-IL10) in combination with Methotrexate was presented at last week’s European League Against Rheumatism (EULAR) Annual Congress in Berlin. DEKAVIL is a targeted anti-inflammatory immunocytokine, which is selectively delivered to disease sites. Preliminary data from the trial, supported by a grant from the Tuscan Council and involving 5 patients to date at the University Hospital of Siena and the San Matteo Clinic in Pavia, indicate the activity of the product. With the exception of one patient, all patients treated to date enjoyed durable ACR50 or ACR70 responses, and there is promising safety data. These data are particularly encouraging as they were observed in the low dose Phase I cohorts, warranting future development of the product in randomized clinical trials.
 
Berlin, Germany, June 6th-9th, 2012
Philogen is pleased to announce that positive data emerging from the Phase Ib Rheumatoid Arthritis clinical trial with DEKAVIL (F8-IL10) in combination with methotrexate will be presented at the European League Against Rheumatism (EULAR) Annual Congress. A Poster entitled 'a phase IB clinical trial with DEKAVIL (F8-IL10), an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis, used in combination with methotrexate' will be presented (Galeazzi et al), and there will also be an oral presentation by Prof. Dario Neri.
 
Berlin, Germany, September 2nd-6th, 2012
Prof. Dario Neri will give a plenary presentation at the symposium ‘Antibody-Drug Conjugates – Finally Ready  for Prime Time’ to be held as part of the EFMC-ISMC XXIInd International Symposium on Medicinal Chemistry. The title of the presentation will be ‘Targeting tumors with antibody-drug conjugates and other armed antibodies: from the bench to the clinic’ .
 
Rimini, Italy, 30th May – 1st  June, 2012
Dr Leonardo Giovannoni, Head of Clinical Operations, will present at the 52nd Symposium of AFI (Associazione Farmaceutici Industria) in Rimini (Italy), 30th May – 1st  June 2012. The title of his presentation will be:  “Philogen’s pipeline in oncology and rheumatoid arthritis: rationale and clinical results”.
 
Prague, April 17th – 20th, 2012
Dr Leonardo Giovannoni, Dr Leonardo Giovannoni, Head of Clinical Operations, will present at the 8th Annual Bioprocess International Conference in Prague, 17th – 20th April 2012. The title of his presentation will be:  “Process Development of armed antibody for the therapy of cancer and rheumatoid arthritis”.
 
Chicago, USA, April 1st -4th, 2012
Prof. Dario Neri will present a plenary lecture at AACR, April 1st -4th Chicago.
 
London, UK, February 15th – 16th, 2012
Dr Leonardo Giovannoni, Head of Clinical Operations, will present at the 5th  Bioinnovation Leaders Summit in London, 15th – 16th February 2012. The title of his presentation will be: “Designing a downstream protein  purification process using recent new developments”.
 
Washington, USA, February 1st-2nd, 2012
Dr. Hans Menssen will present at the ‘World RadioImmunoConjugate Summit – Recognizing the Potential of Radioimmunoconjugates for Cancer Treatment and Imaging’ in Washington, 1st-2nd February, 2012. The title of the presentation will be ‘Clinical Trial Case Study: RIT in Combination with External Beam Radiation’.